Overactive Bladder Treatment market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Pholoho Biotechnology, an innovative company in the field of biotechnology, is proud to announce a significant achievement with the extraction and purification of C-Phycocyanin, a biomolecule derived ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

I am Greek and have thalassemia minor. In general, my red blood cells are much smaller than typical ones, and my iron content ...

Urinary incontinence, or leakage of urine, is a very common condition for women of all ages, ethnicities and backgrounds.

Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

Modern treatment approaches offer numerous options ... Acupuncture shows promise in reducing overactive bladder symptoms and stress incontinence. However, results vary among individuals, and more ...

Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.

Medical experts share their answers to all your questions on bladder problems, from urinary tract infections to odd urine ...